Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Marie José Kersten"'
Autor:
Adrian Bloor, Nicolaus Kröger, Gloria Tridello, Alvaro Urbano-Ispizua, Roberta Di Blasi, Joaquin Martinez-Lopez, František Folber, Josep-Maria Ribera, Elisabetta Metafuni, Robin Sanderson, Marie José Kersten, Catherine Thieblemont, Friso Calkoen, Livia Giannoni, Pim G.N.J. Mutsaers, Matthew Collin, Arnon Nagler, Emma Nicholson, Emmanuel Bachy, Fiona L Dignan, Valentín Ortiz-Maldonado, Dolores Caballero, Johan Maertens, Per Ljungman, Pere Barba, Carlos Pinho Vaz, Francis Ayuk, Mi Kwon, Fabio Ciceri, Stephan Mielke, Pierre Sesques, Nina Knelange, Anne M. Spanjaart, Rafael de la Cámara
Publikováno v:
Scientia
Leukemia, 35(12), 3585-3588. Nature Publishing Group
Leukemia
Leukemia, 35(12), 3585-3588. Nature Publishing Group
Leukemia
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Càncer hematològic; Malalties infeccioses Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cáncer hematológico; Enfermedades infecciosas Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haematological cancer;
Autor:
Arjan Diepstra, Ronald van Eijk, Henriette Levenga, Valeska Terpstra, Joost S.P. Vermaat, Lizan Hardi, Richard Raghoo, Marie José Kersten, Tom van Wezel, Arjen H.G. Cleven, Dina Ruano, Liane te Boome, Inge H. Briaire-de Bruijn, Wietske C. E. den Hartog, Fleur A de Groot, Steven T. Pals, Patty M. Jansen, Isabelle Focke-Snieders, Hendrik Veelken, Pancras C.W. Hogendoorn, Marcel Nijland, Anke van den Berg, Pieternella J. Lugtenburg, Judith V.M.G. Bovée, Alina Nicolae, Karin Kleiverda, Ruben A.L. de Groen, Eduardus F. M. Posthuma, Stefan Böhringer, Lara H Böhmer
Publikováno v:
Blood Adv
Blood Advances, 5(19), 3760-3775. ELSEVIER
Blood Advances, 5(19):2021005215, 3760-3775. AMER SOC HEMATOLOGY
Blood advances, 5(19), 3760-3775. American Society of Hematology
Blood Advances, 5(19), 3760-3775. ELSEVIER
Blood Advances, 5(19):2021005215, 3760-3775. AMER SOC HEMATOLOGY
Blood advances, 5(19), 3760-3775. American Society of Hematology
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal lymphoma subtype. This retrospective study elucidates the currently unknown genetic background of a large clinically well-annotated cohort of DLBCLwith osseous localizations (
Autor:
Irit Avivi, Tom van Meerten, Jenny J. Kim, Marika Sherman, John M. Rossi, Roch Houot, Monique C. Minnema, Jinghui Dong, Martin Wermke, John Kuruvilla, Yan Zheng, Max S. Topp, Kevin W. Song, Saran Vardhanabhuti, Ulrich Dührsen, Adrian Bot, Marie José Kersten, Vicki Plaks, Anne Kerber, Catherine Thieblemont, Pieternella J. Lugtenburg, Krimo Bouabdallah
Publikováno v:
British journal of haematology, 195(3), 388-398. Wiley-Blackwell
The Lancet. Oncology
British Journal of Haematology, 195(3), 388-398. Wiley
British Journal of Haematology, 195(3), 388-398. Wiley-Blackwell Publishing Ltd
The Lancet. Oncology
British Journal of Haematology, 195(3), 388-398. Wiley
British Journal of Haematology, 195(3), 388-398. Wiley-Blackwell Publishing Ltd
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed or refractory large B-cell lymphoma (R/R LBCL). To reduce axi-cel–related toxicity, several exploratory safety managem
Autor:
Coreline N. Burggraaff, Gregor Verhoef, Otto S. Hoekstra, Marie José Kersten, Lidwine W. Tick, Mels Hoogendoorn, Margreet Oosterveld, Daphne de Jong, Nicole C. H. P. van der Burg-de Graauw, Marinus van Marwijk Kooy, Matthijs H Silbermann, Aart Beeker, Marjolein van der Poel, Bart de Keizer, Eva de Jongh, Jeanette K. Doorduijn, Harry R. Koene, Thomas Stauffer Larsen, Memis Y Bilgin, Lara H Böhmer, Joost W. J. van Esser, Peter de Nully Brown, Marcel Nijland, Maria B.L. Leijs, J.F.M. Pruijt, Anne I.J. Arens, Josée M Zijlstra-Baalbergen, Pieternella J. Lugtenburg, Kon-Siong G. Jie, Rolf E. Brouwer, King H. Lam, Rob Fijnheer, Bronno van der Holt, Francesco d'Amore
Publikováno v:
Journal of Clinical Oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(29). American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma : A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of clinical oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-chop with early rituximab intensification for diffuse large b-cell lymphoma : A randomized phase iii trial of the hovon and the nordic lymphoma group (hovon-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of Clinical Oncology, 38, 29, pp. 3377-3387
Journal of Clinical Oncology, 38(29), 3377-3387. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(29):38, 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38, 3377-3387
Lugtenburg, P J, de Nully Brown, P, van der Holt, B, D'Amore, F A, Koene, H R, de Jongh, E, Fijnheer, R, van Esser, J W, Böhmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, van der Burg-de Graauw, N C, Oosterveld, M, Jie, K-S G, Larsen, T S, van der Poel, M W, Leijs, M B, Silbermann, M H, van Marwijk Kooy, M, Beker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, de Keizer, B, Arens, A I, de Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, 38, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418, https://doi.org/DOI: 10.1200/JCO.19.03418
Journal of Clinical Oncology, 38(29). American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma : A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of clinical oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-chop with early rituximab intensification for diffuse large b-cell lymphoma : A randomized phase iii trial of the hovon and the nordic lymphoma group (hovon-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of Clinical Oncology, 38, 29, pp. 3377-3387
Journal of Clinical Oncology, 38(29), 3377-3387. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(29):38, 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38, 3377-3387
Lugtenburg, P J, de Nully Brown, P, van der Holt, B, D'Amore, F A, Koene, H R, de Jongh, E, Fijnheer, R, van Esser, J W, Böhmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, van der Burg-de Graauw, N C, Oosterveld, M, Jie, K-S G, Larsen, T S, van der Poel, M W, Leijs, M B, Silbermann, M H, van Marwijk Kooy, M, Beker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, de Keizer, B, Arens, A I, de Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, 38, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418, https://doi.org/DOI: 10.1200/JCO.19.03418
PURPOSE Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). This randomized trial assessed whether rituximab i
Publikováno v:
Current Opinion in Oncology. 32:408-417
Purpose of review CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a valuable new treatment option for patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. The aim of this review is to give an overview of the pivotal ph
Autor:
Jacobien M. Kieffer, Sonia Ancoli-Israel, Margreet Houmes, Eva de Jongh, Jessie L. de Geus, Huub H. van Rossum, Dick Johan van Spronsen, Heiddis B. Valdimarsdottir, Daniëlle E. J. Starreveld, Flora E. van Leeuwen, Eus J.W. Van Someren, Jos A. Bosch, Eveline M. A. Bleiker, Susan K. Lutgendorf, Erik W.A. Marijt, Cecile P.M. Janus, Mirthe Lanfermeijer, Catharina M. Korse, L. Daniels, Marie José Kersten, Lara H Böhmer, Roel J. de Weijer, Josee M. Zijlstra, William H. Redd, G. Esther A. Habers
Publikováno v:
Cancers, 13(19):4948. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13(19). MDPI
Cancers
Cancers, 13, 19
Starreveld, D E J, Daniels, L A, Kieffer, J M, Valdimarsdottir, H B, de Geus, J, Lanfermeijer, M, van Someren, E J W, Habers, G E A, Bosch, J A, Janus, C P M, van Spronsen, D J, de Weijer, R J, Marijt, E W A, de Jongh, E, Zijlstra, J M, Böhmer, L H, Houmes, M, Kersten, M J, Korse, C M, van Rossum, H H, Redd, W H, Lutgendorf, S K, Ancoli-israel, S, van Leeuwen, F E & Bleiker, E M A 2021, ' Light therapy for cancer-related fatigue in (Non-)hodgkin lymphoma survivors : Results of a randomized controlled trial ', Cancers, vol. 13, no. 19, 4948 . https://doi.org/10.3390/cancers13194948
Cancers, Vol 13, Iss 4948, p 4948 (2021)
Cancers, 13
Cancers, vol 13, iss 19
Cancers; Volume 13; Issue 19; Pages: 4948
Cancers, 13(19):4948. MDPI Multidisciplinary Digital Publishing Institute
Cancers, 13(19). MDPI
Cancers
Cancers, 13, 19
Starreveld, D E J, Daniels, L A, Kieffer, J M, Valdimarsdottir, H B, de Geus, J, Lanfermeijer, M, van Someren, E J W, Habers, G E A, Bosch, J A, Janus, C P M, van Spronsen, D J, de Weijer, R J, Marijt, E W A, de Jongh, E, Zijlstra, J M, Böhmer, L H, Houmes, M, Kersten, M J, Korse, C M, van Rossum, H H, Redd, W H, Lutgendorf, S K, Ancoli-israel, S, van Leeuwen, F E & Bleiker, E M A 2021, ' Light therapy for cancer-related fatigue in (Non-)hodgkin lymphoma survivors : Results of a randomized controlled trial ', Cancers, vol. 13, no. 19, 4948 . https://doi.org/10.3390/cancers13194948
Cancers, Vol 13, Iss 4948, p 4948 (2021)
Cancers, 13
Cancers, vol 13, iss 19
Cancers; Volume 13; Issue 19; Pages: 4948
Cancers, 13(19):4948. MDPI Multidisciplinary Digital Publishing Institute
Simple SummaryCancer-related fatigue (CRF) is one of the most frequently reported symptoms with prevalence rates of 25 to 60 percent in (non-)Hodgkin lymphoma survivors. Several (pilot) studies showed promising effects of light therapy to reduce CRF.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b7ef0f9788a03eb260e3b273e6b4372
https://hdl.handle.net/1887/3270923
https://hdl.handle.net/1887/3270923
Publikováno v:
Bone marrow transplantation, 56(8), 2038-2039. Nature Publishing Group
Bone Marrow Transplantation, 56(8), 2038-2039. Nature Publishing Group
Bone Marrow Transplantation, 56(8), 2038-2039. Nature Publishing Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19d24acddaa0a517ac566083f0232564
https://pure.amc.nl/en/publications/professor-anton-hagenbeek-19482021-father-of-mrd-and-lymphoma-expert(7c89d064-0eeb-467f-b751-df71d73fa7fc).html
https://pure.amc.nl/en/publications/professor-anton-hagenbeek-19482021-father-of-mrd-and-lymphoma-expert(7c89d064-0eeb-467f-b751-df71d73fa7fc).html
Autor:
Olalekan O. Oluwole, Umar Farooq, Lovely Goyal, Patrick J. Stiff, Yi Lin, Yan Zheng, John M. Timmerman, Lisa Johnson, Krimo Bouabdallah, Peter A. McSweeney, Catherine Thieblemont, Marie José Kersten, Javier Munoz, John M. Rossi, Julie M. Vose, Caron A. Jacobson, Jeff McLeroy, Zahid Bashir, Nancy L. Bartlett, Sophie de Guibert, Andre Goy, Irit Avivi, Jenny J. Kim, Tom van Meerten, Dimitrios Tzachanis, Abhinav Deol, Monique C. Minnema
Publikováno v:
British journal of haematology, vol 194, iss 4
British Journal of Haematology
British journal of haematology, 194(4), 690-700. Wiley-Blackwell
British Journal of Haematology, 194(4), 690-700. Wiley
British Journal of Haematology
British journal of haematology, 194(4), 690-700. Wiley-Blackwell
British Journal of Haematology, 194(4), 690-700. Wiley
ZUMA-1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous CD19-directed chimaeric antigen receptor (CAR)-T cell therapy, in refractory large B-cell lymphoma. To reduce treatment-related toxicity, severa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25036bc6aeb6beaaba44629eb3f65d3e
https://escholarship.org/uc/item/11d048rn
https://escholarship.org/uc/item/11d048rn
Autor:
Josée M. Zijlstra, Otto Visser, Avinash G. Dinmohamed, Hidde L. A. Posthuma, Pieternella J. Lugtenburg, Marie José Kersten
Publikováno v:
Blood cancer journal, 11(5):87. Nature Publishing Group
Blood Cancer Journal
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-4 (2021)
Blood Cancer Journal, 11(5):87. Nature Publishing Group
Blood Cancer Journal
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-4 (2021)
Blood Cancer Journal, 11(5):87. Nature Publishing Group
Publikováno v:
Leukemia, 35(9), 2725-2726. Nature Publishing Group